PHIA Koninklijke Philips N.V.

Philips and Paige team up to bring Artificial Intelligence (AI) to clinical pathology diagnostics

Philips and Paige team up to bring Artificial Intelligence (AI) to clinical pathology diagnostics

December 5, 2019

AI-based  cancer assessment tools are poised to help pathologists improve speed and accuracy of cancer diagnostics, ultimately leading to better patient care

Amsterdam, The Netherlands – ( (NYSE: PHG, AEX: PHIA), a global leader in health technology, and , a leader in computational pathology, announced today a strategic collaboration to deliver clinical-grade AI applications to pathology laboratories. These AI technologies, starting with Paige Prostate, aim to help pathologists identify, quantify and characterize cancer in tissue samples and make precise diagnoses more efficiently. This may, ultimately, positively impact pathologist’s workflow and treatment planning for patients.

Pathologists play a crucial role in the detection and diagnosis of a broad range of diseases, including cancer. The increasing number of cancer cases in the aging population, and rapid advances in personalized medicine have resulted in significant increases in the complexity of pathology diagnostics and the workload imposed on pathologists. Digital images of tissue samples make it possible for pathologists to easily diagnose these samples on a computer display using advanced imaging analysis and workflow software.

Paige’s technology has demonstrated , and the collaboration aims to deliver this kind of technology into routine clinical practice. Several pathology laboratories have already converted their glass slide-based workflow to digital, using the solution from Philips. Once digital images are available, the CE marked Paige Prostate software is applied automatically to detect and localize prostate cancer. This technology provides pathologists with valuable information they can use in their evaluation of prostate biopsies.

“We want to empower pathologists with the latest computational pathology solutions to enhance the diagnosis and treatment of cancer,” said Marlon Thompson, Business Leader of Digital & Computational Pathology at Philips. “Through our open digital pathology platform approach, we team up with leading computational pathology solution providers, such as Paige, to create the ultimate end-to-end oncology workflow for our customers.”

“Pathology is transforming into a digital discipline and holds a strong promise for using AI solutions to aid, streamline, and enhance decision-making,” said Leo Grady, CEO of Paige. “Together with digital pathology providers, starting with Philips, one of the leaders in the clinical digital pathology space, we want to convert this promise into a clinical reality that supports pathologists and their patients.”

in combination with Paige Prostate aims to provide an intuitive digital & computational pathology workflow experience. Philips plans to offer the CE-marked Paige Prostate to European pathology labs in 2020. AI solutions for other markets and additional disease areas are expected to follow suit. Visit and  . for more information.

For further information, please contact:

Joost Maltha

Philips Global Press Office

Tel. : 6

Email:  

Nicole Rodrigues

NRPR Group – For Paige

Tel.:

Email:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment, and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring, and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

About Paige.AI

Paige.AI is the leading start-up focused on building the best artificial intelligence in clinical medicine to transform how doctors diagnose and treat cancer. Based in New York, Paige.AI is bringing together the world’s leading experts in AI, computational pathology and clinical practice to improve patient care through a quantum leap forward in efficacy and efficiency. For more information, please visit: .

 

Attachment

EN
05/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation ...

Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of corona...

 PRESS RELEASE

Philips reiterates timing of 2026 outlook

Philips reiterates timing of 2026 outlook December 4, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit gro...

 PRESS RELEASE

Philips expands commercial availability of world’s first real-time AI-...

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy December 1, 2025 Commercial availability expanded across Europe and the United StatesReal-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular proceduresLumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – (NYSE: PHG, AEX: PH...

 PRESS RELEASE

Philips launches Verida, world’s first detector-based spectral CT powe...

Philips launches Verida, world’s first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1]CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, (NYSE: PHG, AEX: PHIA), a global leader in health techno...

 PRESS RELEASE

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MR...

Philips unveils BlueSeal Horizon, industry’s first helium-free 3.0T MRI platform November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry’s first helium-free 3.0T magnet at . A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch